Uni Eropa - Kroasia - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic kiselina - dijabetes mellitus, tip 2 - drugs used in diabetes, sodium-glucose co-transporter 2 (sglt2) inhibitors - steglatro prikazan u odraslih osoba u dobi od 18 godina i stariji sa dijabetesom tipa 2 kao dodatak prehrani i fizičke vježbe za poboljšanje glikemijski kontrole:kao monoterapija kod bolesnika za koje primjena метформина se smatra da je neprimjereno zbog netolerancije ili kontraindikacija. osim drugih lijekova za liječenje šećerne bolesti.

Uni Eropa - Kroasia - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propandiol monohidrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - lijekovi koji se koriste u dijabetesu - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. osim drugih lijekova za liječenje šećerne bolesti tipa 2 . for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 i 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Uni Eropa - Kroasia - EMA (European Medicines Agency)

novartis europharm limited - вилдаглиптин, metformin hidroklorid - dijabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Uni Eropa - Kroasia - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propandiol monohidrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - lijekovi koji se koriste u dijabetesu - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. osim drugih lijekova za liječenje šećerne bolesti tipa 2 . for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 i 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Uni Eropa - Kroasia - EMA (European Medicines Agency)

novartis europharm limited - вилдаглиптин, metformin hidroklorid - dijabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 i 5. 1 za dostupne podatke o različitim kombinacijama).

Uni Eropa - Kroasia - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin, pioglitazone - dijabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - incresync is indicated as a second- or third-line treatment in adult patients aged 18 years and older with type-2 diabetes mellitus: , as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on pioglitazone alone, and for whom metformin is inappropriate due to contraindications or intolerance;, in combination with metformin (i. trostruka kombinirana terapija) kao dodatak prehrani i fizičke vježbe za poboljšanje glikemijski kontrole kod odraslih pacijenata (posebno u pacijenata s viškom težine) neadekvatna na njihovu maksimalnu переносимой doze метформина i пиоглитазона. osim toga , incresync može se koristiti kako bi zamijeniti pojedine tablete alogliptin i pioglitazone u onih odraslih pacijenata u dobi od 18 godina i stariji sa dm-2 već šećerna bolest liječi sa ovom kombinacijom. nakon početka terapije s incresync, pacijenti moraju biti revidiran nakon tri do šest mjeseci, za procjenu adekvatnosti odgovora na liječenje (e. smanjenje pokazatelja hba1c). kod bolesnika koji ne pokazuju adekvatan odgovor, incresync treba prestati. u svjetlu potencijalnih rizika kod duljeg pioglitazone terapija, propisane lijekove treba potvrditi u kasnijim rutinske inspekcije da dobro incresync sprema (vidi odjeljak 4.

Uni Eropa - Kroasia - EMA (European Medicines Agency)

takeda pharma a/s - alogliptin benzoat, метформина hidroklorid - dijabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus:as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin;in combination with pioglitazone (i. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone;in combination with insulin (i. trostruka kombinirana terapija) kao dodatak prehrani i fizičke vježbe za poboljšanje glikemijski kontrole kod bolesnika, kada inzulina u stabilne doze i metformin sami ne pružaju adekvatnu glikemijski kontrole.

Uni Eropa - Kroasia - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic kiselina monohidrat fosfata ситаглиптин - dijabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - steglujan prikazan u odraslih osoba u dobi od 18 godina i stariji sa dijabetesom tipa 2 kao dodatak prehrani i fizičke vježbe za poboljšanje glikemijski kontrole:kada метформина i/ili sulfonilureje (su) i jedan od однокомпонентных od steglujan ne pružaju adekvatnu glikemijski kontrole. kod bolesnika se liječi s kombinacijom ertugliflozin i ситаглиптина kao zasebne tableta.

Kroasia - Kroasia - HALMED (Agencija za lijekove i medicinske proizvode)

abbott laboratories d.o.o., zagreb - glukometar za brzo određivanje koncentracije glukoze u perifernoj krvi i kontrolna otopina

Kroasia - Kroasia - HALMED (Agencija za lijekove i medicinske proizvode)

salvus d.o.o., donja stubica - in vitro dijagnostika, test trake za analizu urina